Skip to main navigation

Skip Navigation

- Landos - Corp Menu

About Us
- Our Company
- Contact Us
Product Candidates
Science
Investors/Media
Careers
- Why Landos?
- Open Positions

Identifying novel pathways at the interface of immunity and metabolism

Press Releases

Year

11/10/22

Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update

9/6/22

Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical Officer

8/11/22

Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update

8/3/22

Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial

6/21/22

Landos Names Gregory Oakes President and Chief Executive Officer

5/12/22

Landos Biopharma Reports First Quarter 2022 Results and Provides Business Update

3/24/22

Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

3/10/22

Landos Biopharma Appoints Roger Adsett to its Board of Directors

Investors/Media

Investor Relations

Investor/Media Home
Press Releases
Events & Presentations
Analyst Coverage
Stock Information
SEC Filings
Corporate Governance
Investors/Media FAQs

- Landos - Investor Tools

Print Page
RSS Feeds
Email Alerts

Contact

Landos Biopharma, Inc.
1800 Kraft Drive, Suite 216
Blacksburg, VA 24060

info@landosbiopharma.com
(540) 218-2232

- Landos - Footer Menu

Site Map
Terms of Use
Privacy Policy

©2022 Landos Biopharma All Rights Reserved.